Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 5/20 | 0.42 |
| ▸ | EIF2AK4 | Q9P2K8 | 7/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | NRAS | P01111 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3315522 | 0.86 | IGF1R (0.44) | FLT3CYP11B1CYP11B2NRASADORA2A | |
| SCHEMBL3310129 | 0.86 | FLT3 (0.43) | FLT3EIF2AK4CYP11B1CYP11B2NRAS | |
| SCHEMBL20455512 | 0.84 | MAP3K14 (0.47) | FLT3EIF2AK4CCNT1CDK9NRAS | |
| SCHEMBL22228712 | 0.83 | EIF2AK4 (0.43) | FLT3EIF2AK4ADORA2A | |
| SCHEMBL20455522 | 0.82 | CLK1 (0.48) | FLT3EIF2AK4CCNT1CDK9NRAS | |
| SCHEMBL23245946 | 0.81 | FLT3 (0.60) | FLT3EIF2AK4CCNT1CDK9 | |
| SCHEMBL22228914 | 0.81 | ALDH1A1 (0.48) | — | |
| SCHEMBL22228697 | 0.78 | FLT3 (0.44) | FLT3EIF2AK4CYP11B1CYP11B2NRAS | |
| SCHEMBL14852933 | 0.78 | JAK2 (0.46) | CYP11B1CYP11B2ADORA2AJAK2JAK1 | |
| SCHEMBL3315346 | 0.78 | DYRK1A (0.46) | FLT3CCNT1CDK9IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | FLT3 191/4885EIF2AK4 844/4885CYP11B1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.